These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1028 related items for PubMed ID: 16636531

  • 1. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.
    Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
    [Abstract] [Full Text] [Related]

  • 3. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Sep; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH, Holzer H, Mayer GJ, Osterreichische Aranesp Studiengruppe.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):967-71. PubMed ID: 12635463
    [Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 30; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 30; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 7. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec 30; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 8. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Dec 30; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 9. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Dec 30; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 10. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb 30; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 11. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep 30; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Sep 30; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 13. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
    Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.
    Hemodial Int; 2010 Apr 30; 14(2):233-9. PubMed ID: 19888948
    [Abstract] [Full Text] [Related]

  • 14. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 30; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group.
    Kidney Int; 2002 Dec 30; 62(6):2167-75. PubMed ID: 12427142
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Dec 30; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 17. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 30; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 18. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr 30; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 19. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar 30; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 20. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 30; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.